Eliquis Insurance Denial Appeal Guide

Why Eliquis Gets Denied

Eliquis competes with Xarelto, Pradaxa, and generic warfarin. Some plans prefer generic warfarin as first-line, while others prefer a competing brand anticoagulant. Prior authorization is standard for all DOACs.

Common Denial Reasons

• Plan requires warfarin trial first (step therapy)
• Non-preferred DOAC (plan prefers Xarelto)
• Prior authorization not submitted
• Dose or quantity not matching approved indication
• Duplicate therapy (already on another anticoagulant)

How to Appeal

1. Document why warfarin is inappropriate — labile INR, dietary restrictions, drug interactions, fall risk, patient compliance concerns
2. If Xarelto is preferred but failed — document GI side effects or bleeding events
3. Cite ARISTOTLE trial — Eliquis showed superior efficacy and safety vs warfarin with less major bleeding
4. Include cardiologist letter supporting Eliquis as best choice for this patient
5. Note renal dosing advantage — Eliquis is preferred in moderate renal impairment

Key Documentation

• CHA2DS2-VASc score for AFib patients
• Renal function (CrCl) — Eliquis has favorable renal dosing
• Prior warfarin history with INR records if available
• Bleeding risk assessment (HAS-BLED score)